Clear Street’s Axsome Therapeutics AXSM Stock Holding History

Clear Street’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-131,500	Closed	-$9.45M	–	1138
2023 Q2	$9.45M	Buy	+131,500	New	+$9.7M	0.09%	143

Other funds holding AXSM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clear Street's AXSM Position: Q3 2023 in Review

Clear Street sold out of Axsome Therapeutics (AXSM) in Q3 2023, closing a stake of 131,500 shares — an estimated $9.45M sold.

Clear Street first reported a position in AXSM in Q2 2023 and held it in 1 quarter. The position peaked at $9.45M in Q2 2023. 226 funds tracked by Wall St. Rank hold AXSM as of Q3 2023.

Clear Street reported no remaining Axsome Therapeutics position as of Q3 2023 after selling out during the quarter.
Clear Street sold 131,500 Axsome Therapeutics shares in Q3 2023, an estimated $9.45M.
Clear Street first reported a position in Axsome Therapeutics in Q2 2023 and held it in 1 quarter.
Clear Street's Axsome Therapeutics position peaked at $9.45M in Q2 2023.
226 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2023.

Based on Clear Street's 13F filing for Q3 2023, filed 13 Nov 2023.